255 related articles for article (PubMed ID: 15339673)
21. Bone marrow histopathology in myeloproliferative disorders--current diagnostic approach.
Thiele J; Kvasnicka HM; Orazi A
Semin Hematol; 2005 Oct; 42(4):184-95. PubMed ID: 16210032
[TBL] [Abstract][Full Text] [Related]
22. Early down-regulation of Bcl-xL expression during megakaryocytic differentiation of thrombopoietin-induced CD34+ bone marrow cells in essential thrombocythemia.
Zhang L; Zhao H; Sun A; Lu S; Liu B; Tang F; Feng Y; Zhao L; Yang R; Han ZC
Haematologica; 2004 Oct; 89(10):1199-206. PubMed ID: 15477204
[TBL] [Abstract][Full Text] [Related]
23. Prognostic significance of bone marrow biopsy in essential thrombocythemia.
Annaloro C; Lambertenghi Deliliers G; Oriani A; Pozzoli E; Lambertenghi Deliliers D; Radaelli F; Faccini P
Haematologica; 1999 Jan; 84(1):17-21. PubMed ID: 10091388
[TBL] [Abstract][Full Text] [Related]
24. VEGF expression correlates with microvessel density in Philadelphia chromosome-negative chronic myeloproliferative disorders.
Gianelli U; Vener C; Raviele PR; Savi F; Somalvico F; Calori R; Iurlo A; Radaelli F; Fermo E; Bucciarelli P; Bori S; Coggi G; Deliliers GL
Am J Clin Pathol; 2007 Dec; 128(6):966-73. PubMed ID: 18024322
[TBL] [Abstract][Full Text] [Related]
25. [The morphology features of bone marrow in the prefibrotic-early primary myelofibrosis].
Gong XB; Zhang XH; Lu XG; Tang QS; Gao X; Yang J
Zhonghua Xue Ye Xue Za Zhi; 2012 Jan; 33(1):25-30. PubMed ID: 22575188
[TBL] [Abstract][Full Text] [Related]
26. [Prognostic value of bone marrow biopsy in chronic myeloproliferative disorders].
Bettini R; Marzetta K; Miglioranza A; Redaelli S; Maino C; Maffiolini A; Gorini M
Recenti Prog Med; 2003; 94(7-8):314-20. PubMed ID: 12868237
[TBL] [Abstract][Full Text] [Related]
27. The incidence of myelofibrosis in essential thrombocythaemia, polycythaemia vera and chronic idiopathic myelofibrosis: a retrospective evaluation of sequential bone marrow biopsies.
Kreft A; Büche G; Ghalibafian M; Buhr T; Fischer T; Kirkpatrick CJ
Acta Haematol; 2005; 113(2):137-43. PubMed ID: 15802893
[TBL] [Abstract][Full Text] [Related]
28. Clinical correlation of bone marrow microvessel density in essential thrombocythemia.
Panteli K; Zagorianakou N; Agnantis NJ; Bourantas KL; Bai M
Acta Haematol; 2005; 114(2):99-103. PubMed ID: 16103633
[TBL] [Abstract][Full Text] [Related]
29. Clinical utility of the absolute number of circulating CD34-positive cells in patients with chronic myeloproliferative disorders.
Passamonti F; Vanelli L; Malabarba L; Rumi E; Pungolino E; Malcovati L; Pascutto C; Morra E; Lazzarino M; Cazzola M
Haematologica; 2003 Oct; 88(10):1123-9. PubMed ID: 14555308
[TBL] [Abstract][Full Text] [Related]
30. [Jamshidi biopsy in clinical hematology. Method, indications and results of over 1,000 completed biopsies with special reference to chronic myeloproliferative diseases].
Seewann HL
Wien Med Wochenschr Suppl; 1986; 100():1-24. PubMed ID: 3471009
[TBL] [Abstract][Full Text] [Related]
31. The role of beta-catenin in chronic myeloproliferative disorders.
Jauregui MP; Sanchez SR; Ewton AA; Rice L; Perkins SL; Dunphy CH; Chang CC
Hum Pathol; 2008 Oct; 39(10):1454-8. PubMed ID: 18619646
[TBL] [Abstract][Full Text] [Related]
32. Philadelphia (Ph) chromosome-positive thrombocythemia without features of chronic myeloid leukemia in peripheral blood: natural history and diagnostic differentiation from Ph-negative essential thrombocythemia.
Michiels JJ; Berneman Z; Schroyens W; Kutti J; Swolin B; Ridell B; Fernando P; Zanetto U
Ann Hematol; 2004 Aug; 83(8):504-12. PubMed ID: 15164229
[TBL] [Abstract][Full Text] [Related]
33. Megakaryopoiesis in chronic myeloproliferative diseases. A morphometric evaluation with special emphasis on primary thrombocythemia.
Thiele J; Funke S; Holgado S; Choritz H; Georgii A
Anal Quant Cytol; 1984 Sep; 6(3):155-67. PubMed ID: 6594964
[TBL] [Abstract][Full Text] [Related]
34. CD34+ progenitor cells in idiopathic (primary) myelofibrosis: a comparative quantification between spleen and bone marrow tissue.
Thiele J; Kvasnicka HM; Czieslick C
Ann Hematol; 2002 Feb; 81(2):86-9. PubMed ID: 11907788
[TBL] [Abstract][Full Text] [Related]
35. Bone marrow histopathology and biological markers as specific clues to the differential diagnosis of essential thrombocythemia, polycythemia vera and prefibrotic or fibrotic agnogenic myeloid metaplasia.
Michiels JJ
Hematol J; 2004; 5(2):93-102. PubMed ID: 15048058
[TBL] [Abstract][Full Text] [Related]
36. Single chromosomal abnormalities in Philadelphia-negative chronic myeloproliferative disorders.
Panani AD
In Vivo; 2007; 21(5):867-70. PubMed ID: 18019426
[TBL] [Abstract][Full Text] [Related]
37. Clinicopathological criteria for differential diagnosis of thrombocythemias in various myeloproliferative disorders.
Thiele J; Kvasnicka HM
Semin Thromb Hemost; 2006 Apr; 32(3):219-30. PubMed ID: 16673276
[TBL] [Abstract][Full Text] [Related]
38. Aberrant expression of insulin-like growth factor-2 (IGF-2) in Philadelphia chromosome negative chronic myeloproliferative disorders.
Bock O; Tessema M; Serinsöz E; von Wasielewski R; Büsche G; Kreipe H
Leuk Res; 2004 Nov; 28(11):1145-51. PubMed ID: 15380337
[TBL] [Abstract][Full Text] [Related]
39. Different immunophenotypical apoptotic profiles characterise megakaryocytes of essential thrombocythaemia and primary myelofibrosis.
Florena AM; Tripodo C; Di Bernardo A; Iannitto E; Guarnotta C; Porcasi R; Ingrao S; Abbadessa V; Franco V
J Clin Pathol; 2009 Apr; 62(4):331-8. PubMed ID: 19329711
[TBL] [Abstract][Full Text] [Related]
40. Thrombopoietin receptor (Mpl) expression by megakaryocytes in myeloproliferative disorders.
Bock O; Schlué J; Mengel M; Büsche G; Serinsöz E; Kreipe H
J Pathol; 2004 May; 203(1):609-15. PubMed ID: 15095485
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
